Table 5.
Member States of the WHO European region reporting on surveillance-related activities by EU/EEA membership
| EU/EEA | non-EU/EEA | ||||
|---|---|---|---|---|---|
| N = 25 | % | N = 19 | % | p-value | |
| National coordination | |||||
| Existence of a written national strategy or plan that focuses exclusively or primarily on the prevention and control of viral hepatitis and includes a surveillance component | 6 | 24.0 | 6 | 31.6 | 0.412 |
| Routine surveillance of viral hepatitis B and C | |||||
| National surveillance system for acute HBV | 25 | 100 | 18 | 94.7 | 0.432 |
| National surveillance system for acute HCV | 23 | 92.0 | 18 | 94.7 | 0.604 |
| National surveillance system for chronic HBV | 18 | 72.0 | 10 | 52.6 | 0.157 |
| National surveillance system for chronic HCV | 17 | 68.0 | 10 | 52.6 | 0.234 |
| Standard case definitions for viral hepatitis infections | 25 | 100 | 17 | 89.5 | 0.181 |
| Regular hepatitis disease reports published | 22 | 88.0 | 17 | 89.5 | 0.632 |
| Hepatitis outbreaks required to be reported to the government and further investigated | 23 | 92.0 | 19 | 100 | 0.317 |
| Adequate laboratory capacity nationally to support hepatitis outbreak investigations and other surveillance activities for HBV and HBC | 25 | 100 | 19 | 100 | - |
| Other sources of strategic information and capacities for disease burden estimation | |||||
| Deaths, including from hepatitis, reported to a central registry | 25 | 100 | 17 | 89.5 | 0.181 |
| Liver cancer cases registered nationally | 22 | 88.0 | 13 | 68.4 | 0.122 |
| Cases of HIV/hepatitis co-infection registered nationally | 16 | 64.0 | 13 | 68.4 | 0.508 |
| Viral hepatitis serosurveys conducted regularly | 10 | 40.0 | 10 | 52.6 | 0.299 |
| If yes, please specify the target populations: | |||||
| - children | 3 | 12.0 | 2 | 10.5 | 0.632 |
| - general population | 8 | 32.0 | 3 | 15.8 | 0.191 |
| - people who inject drugs | 6 | 24.0 | 6 | 31.6 | 0.412 |
| - men who have sex with men | 3 | 12.0 | 6 | 31.6 | 0.112 |
| - other groups | 7 | 28.0 | 10 | 52.6 | 0.089 |
| All pregnant women screened for HBV | 21 | 84.0 | 13 | 68.3 | 0.195 |
| All donated blood (including family donations) screened for HBV | 25 | 100 | 17a | 94.4 | 0.419 |
| All donated blood (including family donations) screened for HCV | 25 | 100 | 18a | 100 | 0.432 |
| Areas in which Member States might want assistance from WHO | |||||
| National plan | 6 | 24.0 | 11 | 57.9 | 0.024 |
| Surveillance | 2 | 8.0 | 8 | 42.1 | 0.010 |
| Burden estimation | 6 | 24.0 | 9 | 47.4 | 0.097 |
aAndorra is not included in this calculation because Andorra does not have blood donation centres